Background: To assess the outcome after meningioma surgery and protontherapy (PT). Methods: We processed the French Système National des Données de Santé database to retrieve appropriate cases of meningiomas operated and irradiated between 2008 and 2017. Survival methods were implemented. Results: One hundred ninety-three patients who received PT after meningioma surgery over a 10-year period were identified. Of the 193 patients, 75.6% were female. Median age at surgery was 50 years (interquartile range [IQR] 41-62). The median number of PT fractions was 31 (IQR 30-39) given over a median duration of 52 days (IQR 44-69). Fourteen patients (7.3%) also received photon radiotherapy and six patients (3.1%) stereotactic radiosurgery. Median follow-up was 4.4 years (IQR 3.86-4.71). Five-year progression-free survival (PFS) rate was 69% (95% confidence interval [CI] 62.1–76.6). For benign, atypical, and malignant meningioma, 5-year PFS rates were 71.5% (95% CI 64.4-79.4), 55.6% (95% CI 32.5-95), and 35.6% (95% CI 12.8-98.9), respectively (p<0.01). In the adjusted regression, tumour location (hazard ratio [HR]=0.1, 95% CI 0.05-0.22, p<0.001), aggressive meningioma (HR=2.26, 95% CI 1.1-4.66, p=0.027), and the need of cerebrospinal fluid (CSF) insertion for hydrocephalus (HR=3.51, 95% CI 1.32-9.31, p=0.012) remained significantly associated to the PFS. All grades considered, 5-year overall survival (OS) rates was 89.7% (95% CI 84.6-95.1). For benign, atypical, and malignant meningioma, 5-year OS rates were 93% (95% CI 88.7-97.4), 76.4% (95% CI 51.4-100), and 44.4% (95% CI 16.7-100), respectively (p<0.01). In the multivariable regression, an older age above 70 years (HR=5.95, 95% CI 2.09-16.89, p<0.001) associated to a high level of comorbidities (HR=5.31, 95% CI 1.43-19.78, p=0.013) and a malignant meningioma (HR=5.68, 95% CI 1.54-20.94, p=0.009) remained significantly associated to a reduced OS. Conclusion Five-year PFS and OS after meningioma surgery and PT is favourable but impaired for older patients with high level of morbidities, tumour of the convexity, malignant histopathology and for those requiring CSF shunting. Further inclusion and prolonged follow-up is required to assess other predictors such as sex, tumour volume, or given dose.

Methods: We performed an analytical retrospective cohort study at five different institutions. All patients with a diagnosis of SM were included in this study, including those with recurrent tumors. Meningiomas of the foramen magnum were excluded. Useful histopathological characteristics were separately extracted. Surgical resection was evaluated according to the Simpson grading scale. Patient outcomes and clinical states were assessed with the help of their medical records using four different scales: the modified Ranawat score, the Nurick scale, the Prolo score, the Frankel grade, and the Eastern Cooperative Oncology Group–World Health Organization– Zubrod score. Results: Between 1991 and 2018, 417 patients were identified, of which 85.8% were female. The median age at surgery was 67.2 years (interquartile range [IQR], 56.7–76.5). The lesion was located in the thoracic region in 77.9% of the patients, cervical region in 16.8%, and lumbar region in 4.1%. Surgical resection was complete in 95.5% of the cases. Only 0.96% of the patients died within the first postoperative month. Neurological status, which improved in 76.9% of the patients, was unchanged in 17.5% and even worsened in 4.4%. Functional status was assessed using the Ranawat score and Nurick scale, with scores of 1 (IQR, 0–2) (i.e., hyperreflexia and asymptomatic; mean, 1.3±1.3) and 1 (IQR, 0−2) (i.e., signs of spinal cord disease, but no difficulty in walking; mean, 1.2±1.4), respectively. Approximately 10.1% of the patients were not ambulant at the last neurosurgical follow-up visit. Older age at surgery was not significantly associated with a chair-bound status (p =0.427). Conclusions This large series confirms the favorable FO after spinal meningioma surgery even in the case of seriously impaired preoperative status. A validated scale is needed to assess the factors predicting a worsening of the functional status and guide the management of patients.

Methods: The current study processed the Système National des Données de Santé (SNDS), the French national administrative medical database, to retrieve appropriate cases. Results: This study identified 2,844 patients (79.1% females) between 2008 and 2017. The median age at surgery was 66 years (interquartile range [IQR], 56–75 years). Moreover, 95.9% of SMs were removed through posterior or posterolateral approaches, and 6.9% were epidural and 0.7% needed an associated spine stabilization. Benign meningioma represented 92.9%, with 5% and 2.1% atypical and malignant, respectively. The median follow-up was 3.3 years (IQR, 3.1–3.5 years). Of the patients, 0.25% and 1.2% expired within a month and a year of surgery, respectively. At data collection, 225 patients (7.9%) expired. The 5-year overall survival (OS) probability was 90.1% (95% CI, 88.6%–91.7%). However, absolute excess risk of mortality after SM surgery was null, and the related standardized mortality ratio was 1 (95% CI, 0.9–1.2; p =0.565). In the adjusted regression, age at surgery (hazard ratio [HR], 1.06; 95% CI, 1.04–1.07; p <0.001), level of comorbidities (HR, 1.44; 95% CI, 1.34–1.54; p <0.001), neurofibromatosis type 2 (NF2; HR, 3.65; 95% CI, 1.28–10.39; p =0.0152), epidural SM (HR, 1.73; 95% CI, 1.09–2.75; p =0.0206), and malignant meningioma (HR, 2.64; 95% CI, 1.51–4.61; p <0.001) remained significantly associated to a reduced OS. Conclusions The SNDS is of great value in assessing SM incidence, associated mortality, and its predictors. OS after meningioma surgery is favorable but may be impaired for NF2 or older patients with a high level of comorbidities, epidural tumor, and malignant histopathology. SM surgery is not associated with an increased absolute excess mortality risk despite being performed on even more senior patients compared with intracranial meningioma.

A 35 years old woman presented with an acute meningeal syndrome following an intra ventricular haemorrhage without subarachnoid haemorrhage. The angiography demonstrated a 6 mm partially thrombosed saccular aneurysm at the plexal point of the right anterior choroidal artery (AChoA). It was surgically approached inside the ventricle through a trans-temporal corticotomy. The aneurysm was excised after distal exclusion of the feeding artery under motor-evoked potentials monitoring. Of the 19 cases of distal AChoA aneurysm neurosurgical treatment, this is the only one performed under electrophysiology monitoring, a simple and safe method to detect and prevent motor tract ischemia. We discuss this rare case, along with a comprehensible review of the literature of the previous surgical cases of distal AChoA aneurysms.
Aneurysm* ; Angiography ; Arteries* ; Choroid* ; Electrophysiology ; Evoked Potentials, Motor ; Female ; Humans ; Intracranial Aneurysm ; Ischemia ; Methods

Background: This study aimed to assess the overall survival (OS) of patients after high-grade glio-ma (HGG) resection and to search for associated prognostic factors. Methods: A random sample of ad hoc cases was extracted from the French medico-adminis-trative national database, Système National des Données de Santé (SNDS). We solely considered the patients who received chemoradiotherapy with temozolomide (TMZ/RT) after HGG surgery. Statistical survival methods were implemented. Results: A total of 1,438 patients who had HGG resection at 58 different institutions between2008 and 2019 were identified. Of these, 34.8% were female, and the median age at HGG resection was 63.2 years (interquartile range [IQR], 55.6–69.4 years). Median OS was 1.69 years (95% confidence interval [CI], 1.63–1.76), i.e., 20.4 months. Median age at death was 65.5 years (IQR, 58.5–71.8). OS at 1, 2, and 5 years was 78.5% (95% CI, 76.4–80.7), 40.3% (95% CI, 37.9–43), and 11.8% (95% CI, 10.2–13.6), respectively. In the adjusted Cox regression, female gender (HR=0.71; 95% CI, 0.63– 0.79; p<0.001), age at HGG surgery (HR=1.02; 95% CI, 1.02–1.03; p<0.001), TMZ treatment over 6 months after HGG surgery (HR=0.36; 95% CI, 0.32–0.4; p<0.001), bevacizumab (HR=1.22; 95% CI, 1.09–1.37; p<0.001), and redo surgery (HR=0.79; 95% CI, 0.67–0.93; p=0.005) remained significantly associated with the outcome. Conclusion The SNDS is a reliable source for studying the outcome of HGG patients. OS is better in younger patient, female gender, and those who complete concomitant chemoradiotherapy. Redo surgery for HGG recurrence was also associated with prolonged survival.

Background: This study aimed to assess the overall survival (OS) of patients after high-grade glio-ma (HGG) resection and to search for associated prognostic factors. Methods: A random sample of ad hoc cases was extracted from the French medico-adminis-trative national database, Système National des Données de Santé (SNDS). We solely considered the patients who received chemoradiotherapy with temozolomide (TMZ/RT) after HGG surgery. Statistical survival methods were implemented. Results: A total of 1,438 patients who had HGG resection at 58 different institutions between2008 and 2019 were identified. Of these, 34.8% were female, and the median age at HGG resection was 63.2 years (interquartile range [IQR], 55.6–69.4 years). Median OS was 1.69 years (95% confidence interval [CI], 1.63–1.76), i.e., 20.4 months. Median age at death was 65.5 years (IQR, 58.5–71.8). OS at 1, 2, and 5 years was 78.5% (95% CI, 76.4–80.7), 40.3% (95% CI, 37.9–43), and 11.8% (95% CI, 10.2–13.6), respectively. In the adjusted Cox regression, female gender (HR=0.71; 95% CI, 0.63– 0.79; p<0.001), age at HGG surgery (HR=1.02; 95% CI, 1.02–1.03; p<0.001), TMZ treatment over 6 months after HGG surgery (HR=0.36; 95% CI, 0.32–0.4; p<0.001), bevacizumab (HR=1.22; 95% CI, 1.09–1.37; p<0.001), and redo surgery (HR=0.79; 95% CI, 0.67–0.93; p=0.005) remained significantly associated with the outcome. Conclusion The SNDS is a reliable source for studying the outcome of HGG patients. OS is better in younger patient, female gender, and those who complete concomitant chemoradiotherapy. Redo surgery for HGG recurrence was also associated with prolonged survival.

Background: This study aimed to assess the overall survival (OS) of patients after high-grade glio-ma (HGG) resection and to search for associated prognostic factors. Methods: A random sample of ad hoc cases was extracted from the French medico-adminis-trative national database, Système National des Données de Santé (SNDS). We solely considered the patients who received chemoradiotherapy with temozolomide (TMZ/RT) after HGG surgery. Statistical survival methods were implemented. Results: A total of 1,438 patients who had HGG resection at 58 different institutions between2008 and 2019 were identified. Of these, 34.8% were female, and the median age at HGG resection was 63.2 years (interquartile range [IQR], 55.6–69.4 years). Median OS was 1.69 years (95% confidence interval [CI], 1.63–1.76), i.e., 20.4 months. Median age at death was 65.5 years (IQR, 58.5–71.8). OS at 1, 2, and 5 years was 78.5% (95% CI, 76.4–80.7), 40.3% (95% CI, 37.9–43), and 11.8% (95% CI, 10.2–13.6), respectively. In the adjusted Cox regression, female gender (HR=0.71; 95% CI, 0.63– 0.79; p<0.001), age at HGG surgery (HR=1.02; 95% CI, 1.02–1.03; p<0.001), TMZ treatment over 6 months after HGG surgery (HR=0.36; 95% CI, 0.32–0.4; p<0.001), bevacizumab (HR=1.22; 95% CI, 1.09–1.37; p<0.001), and redo surgery (HR=0.79; 95% CI, 0.67–0.93; p=0.005) remained significantly associated with the outcome. Conclusion The SNDS is a reliable source for studying the outcome of HGG patients. OS is better in younger patient, female gender, and those who complete concomitant chemoradiotherapy. Redo surgery for HGG recurrence was also associated with prolonged survival.

Background: This study aimed to assess the overall survival (OS) of patients after high-grade glio-ma (HGG) resection and to search for associated prognostic factors. Methods: A random sample of ad hoc cases was extracted from the French medico-adminis-trative national database, Système National des Données de Santé (SNDS). We solely considered the patients who received chemoradiotherapy with temozolomide (TMZ/RT) after HGG surgery. Statistical survival methods were implemented. Results: A total of 1,438 patients who had HGG resection at 58 different institutions between2008 and 2019 were identified. Of these, 34.8% were female, and the median age at HGG resection was 63.2 years (interquartile range [IQR], 55.6–69.4 years). Median OS was 1.69 years (95% confidence interval [CI], 1.63–1.76), i.e., 20.4 months. Median age at death was 65.5 years (IQR, 58.5–71.8). OS at 1, 2, and 5 years was 78.5% (95% CI, 76.4–80.7), 40.3% (95% CI, 37.9–43), and 11.8% (95% CI, 10.2–13.6), respectively. In the adjusted Cox regression, female gender (HR=0.71; 95% CI, 0.63– 0.79; p<0.001), age at HGG surgery (HR=1.02; 95% CI, 1.02–1.03; p<0.001), TMZ treatment over 6 months after HGG surgery (HR=0.36; 95% CI, 0.32–0.4; p<0.001), bevacizumab (HR=1.22; 95% CI, 1.09–1.37; p<0.001), and redo surgery (HR=0.79; 95% CI, 0.67–0.93; p=0.005) remained significantly associated with the outcome. Conclusion The SNDS is a reliable source for studying the outcome of HGG patients. OS is better in younger patient, female gender, and those who complete concomitant chemoradiotherapy. Redo surgery for HGG recurrence was also associated with prolonged survival.